Clinical Profile of Systemic Sclerosis by Subramaniyan, K
CLINICAL PROFILE OF SYSTEMIC SCLEROSIS 
 
 
 
 
 
 
 
 
 
 
Dissertation submitted for 
M.D. Degree Examination Branch I 
GENERAL MEDICINE 
 
 
 
 
 
 
THE TAMILNADU DR.M.G.R. MEDICAL UNIVERSITY, 
CHENNAI 
 
 
MARCH 2007 
 
  
 
 
CERTIFICATE 
 
 
         This is to certify that the dissertation titled “CLINICAL PROFILE OF 
SYSTEMIC SCLEROSIS” is the bonafide original work of 
DR.K.SUBRAMANIYAN in partial fulfillment of the requirements for  
M.D. Branch – I (General Medicine) Examination of the Tamilnadu DR. M.G.R 
Medical University to be held in MARCH 2007.  The Period of study was from  
October 2005 and September 2006. 
 
 
     
   
 
 
 
 
 
 
 
Prof. Dr. D.R. GUNASEKARAN, M.S., F.I.C.S. 
DEAN 
Govt. Stanley Medical College & Hospital, 
Chennai – 600 001. 
 
   
 
                                                                   
 
      Prof.Dr. S. NATARAJAN, M.D. 
      Professor and Head of the  
      Dept. of Medicine, 
      Govt. Stanley Medical College  
      and  Hospital 
      Chennai-600 001.
 
 
 
 
                                                    DECLARATION 
 
 
           I, DR.K.SUBRAMANIYAN, solemnly declare that dissertation titled    
“CLINICAL PROFILE OF SYSTEMIC SCLEROSIS” is a bonafide work 
done by me at Government Stanley Medical College and Hospital from  
2005 - 2006  under the guidance and supervision of my unit chief  
Prof.Dr. S.NATARAJAN, M.D.,  Professor and Head of Department of Medicine, 
Government Stanley Medical College and Hospital, Chennai. 
            This dissertation is submitted to Tamilnadu DR. M.G.R Medical 
University, towards partial fulfillment of requirement for the award of  
M.D. Degree (Branch – I) in General Medicine – March 2007. 
 
Place : Chennai. 
 
Date :  
 
                                                                  
 
                                                                                 (DR. K.SUBRAMANIYAN) 
 
 
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGEMENT 
 
 
         I   owe my   thanks to   the Dean, Govt.  Stanley   Medical   College   and  
 
Hospital, Dr. D.R.GUNASEKARAN, M.S, F.I.C.S. for allowing me to avail the  
 
facilities needed for my dissertation work. 
 
 
         I am grateful to Prof. S. NATARAJAN, M.D., Professor and Head of the  
 
Department of   Medicine,  Govt.  Stanley  Medical   College   and    Hospital   for  
 
Permitting me to do the study and for his encouragement. 
 
         I am extremely thankful to Prof.Dr.S.SHIVAKUMAR,  M.D., Professor of 
Therapeutics, Government Stanley Mecial College & Hospital for his valuable 
assistance and guidance. 
 
         I am indebted to Dr.R. PORKODI, M.D., D.M.(Rheumaology) Assistant 
Professor of Rheumatology, Government Stanley Medical College and Hospital, 
without her help the study would not have been possible.  
 
         I owe my sincere thanks to my Assistant Professors   
 
Dr. M.D.SELVAM, M.D. ,  and Dr. R.S.MURALIDHARAN, M.D., for  their  
 
Valuable advice and appropriate suggestions. 
 
                                                                                                          
                                                                   
         Last but not the least, my sincere thanks to all the patients who co-operated  
 
for  this   study, without whom this study could not have been undertaken and to  
 
all my colleagues who shared their knowledge about the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONTENTS 
 
               PAGE NO  
 
  
 
          1. INTRODUCTION                 
      
    2. AIMS  OF  THE STUDY               
 
    3. REVIEW  OF  LITERATURE                             
 
  4. MATERIALS AND METHODS                    
 
    5. OBSERVATION AND INTERPRETATIONS 
 
    6. RESULTS                         
 
       7. DISCUSSION                                               
 
    8. CONCLUSIONS                          
 
            9. REFERENCES AND BIBLIOGRAPHY                             
            
 10. MASTER  CHART 
   
           11.  PROFORMA 
 
 
 1
 
INTRODUCTION 
 
 
SYSTEMIC SCLEROSIS (SSc)               
 
 
         Systemic sclerosis is a chronic multisystem disorder of unknown etiology 
characterized clinically by thickening of the skin caused by accumulation of 
collagen and by structural and functional abnormalities of visceral organs 
including the gastro intestinal tract, lungs, heart and kidneys1. 
 
         Systemic sclerosis is often of tragic consequence to patients.  Survival is 
determined by the severity of visceral disease, especially involving the lungs, heart 
and/or kidneys. 
 
         Earlier reports indicate that SSc rare in Asian Indian, Chinese and 
Malaysian8,9.   
 
         Contrary to this, later reports from India definitely have shown SSc is not 
uncommon in India, with a distinctly different clinical picture compared to that 
observed in the Western Countries10,11,12,13,14.   
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AIMS OF THE STUDY 
 
 
 
1.       To study the clinical spectrum of patients presenting with 
            Systemic Sclerosis (SSc) 
 
2.         To evaluate the internal organ involvement 
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SYSTEMIC SCLEROSIS 
 
 
HISTORICAL REVIEW2 
 
 
 
         The first convincing description was in 1753 by Carlo Curzio.  He described 
a 17-year-old patient as having ‘extensive tension and hardness of skin all over her 
body’.  Curzio managed the case with bloodletting, warm milk and ‘small doses of 
quick silver’.  However, it was only in the mid 19th century that scleroderma was 
established as a clinical entity and given its current name.  In reviewing the 
described cases to date, Glintrac, in 1847, ascribed the name sclerodermie.  
Maurice Raynaud described Raynaud’s phenomenon in 1865 and Jonathan 
Hutchinson reported a case with Raynaud’s phenomenon who had definite features 
of scleroderma in 1883.  William Osler referred to the systemic nature of the 
disease in his 1894 textbook of medicine (patients were ‘apt to succumb to 
pulmonary complaints or to nephritis’) and Klemperer, Pollack and Baehr, in 
1942, proposed that scleroderma should be considered as a ‘systemic disease of 
the connective tissue.  It was not until 1945, however, that Goetz proposed the 
term progressive systemic sclerosis to emphasize the degree of visceral disease.  
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         In 1964, Winter Bauer described the CRST syndrome (now the CREST 
syndrome of calcinosis, Raynaud’s phenomenon, esophageal dysmotility, 
sclerodactyly and telangiectasia), although it was first described in 1910 and 
originally termed Thiberge – Weissenbach syndrome after the presenting 
physicians.  In 1969 a major pathologic review delineated the widespread fibrotic 
and vascular disease of scleroderma.  Clinical and pathologic surveys of patients 
with scleroderma followed, giving new insight into the clinical features, risk 
factors, pathogenesis of fibrosis and associations of scleroderma with the immune 
response.  In the last decade, there has been remarkable progress in understanding 
the molecular mechanisms of fibrosis, micro vascular injury and the autoimmune 
process in this rare disease.   
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REVIEW OF THE LITERATURE  
 
SYSTEMIC SCLEROSIS2 (SSc) 
 
         Systemic sclerosis is a disfiguring multi system disease that may alter every 
aspect of an individual’s life.  It includes a broad spectrum of disease with varying 
degree of organ involvement.  This subset of patients exist with unique clinical 
features and distinct outcomes. 
 
         Raynaud’s phenomenon, the manifestation of perturbation of the terminal 
arteries of the circulatory system.  This outward manifestation of vascular disease 
is a marker of tissue ischemia that is linked to a progressive fibrosing process in 
specific target organs; the skin, lung, heart, gastrointestinal tract and kidney. 
 
         In the diffuse cutaneous variant systemic sclerosis, fibrosis of skin and other 
organs is widespread and potentially life threatening.  In the limited form of 
systemic sclerosis the skin fibrosis is limited to the fingers and/or distal limbs with 
a more benign and indolent disease course.  Limited cutaneous systemic sclerosis 
is less likely to be associated with serious internal organ involvement. 
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CLASSIFICATION OF SYSTEMIC SCLEROSIS (SCLERODERMA)3 
 
 
DIFFUSE CUTANEOUS SCLERODERMA  
               
         Skin thickening present on the trunk in addition to the face, proximal and 
distal extremities. 
LIMITED CUTANEOUS SCLERODERMA 
 
         Skin thickening limited to sites distal to the elbow and knee but also 
involving face and neck.  This subset frequently has features of the CREST 
Syndrome  ( C = Calcinosis; R = Raynaud’s phenomenon; E = Esophageal 
dysmotility: S = Sclerodactyly; T = Telangiectasia) 
 
SINE SCLERODERMA            
 
         Characteristic internal organ manifestation, vascular and serological 
abnormalities but without clinically detectable skin change. 
 
OVERLAP SYNDROME 
 
         Any of the three previous classification occurring concomitantly with a 
diagnosis of systemic lupus erythematosus (SLE) inflammatory muscle disease 
(or) Rheumatoid Arthritis. 
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UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE  
 
         Raynaud’s phenomenon with clinical and/or serologic features of systemic 
sclerosis (digital ulceration, abnormal nail fold capillary loops, serum 
anticentromere antibody, finger edema) but without skin thickening and without 
internal organ abnormalities of systemic sclerosis. 
 
CRITERIA FOR CLASSIFICATION3,42 
 
         The American College of Rheumatology (former American Rheumatism 
Association) has defined criteria that are 97% sensitive and 98% specific for SSc 
as follows: 
 
Major Criteria 
 
         Sclerodermatous skin change in any location 
         Proximal to the Metacarpophalangeal joints 
 
Minor criteria  
 
♣ Sclerodactyly 
♣ Digital pitting scars of finger tips (or) 
♣ Loss of digital finger pad substance    and  
♣ Bibasillar pulmonary fibrosis 
Diagnosis 
 
         One Major criteria (or) two or  three minor criteria 
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INCIDENCE AND  EPIDEMIOLOGY 
 
         The incidence of systemic sclerosis derived from modern, well designed 
studies is between 18 and 20 individuals per millions of population per year4,5.   
         SSc is found in all geographic areas and all racial groups, although blacks 
may be at moderately increased risk6,7.   
         SSc affects all age groups onset of disease between the ages of 30 and 50 
years4,5,6,7. 
         SSc three to four times more common in women than in men6,7. 
 
         Earlier reports indicate that SSc rare in Asian Indian, Chinese and 
Malaysian8,9.  Contrary to this, later reports from India have definitely shown SSc 
is not uncommon  and occurs with a distinctly different clinical picture compared 
to that observed in the Western countries10,11,12,13,14. 
         Occupational silica or metal dust exposure has been linked with occurrence 
of SSc15.  Although the disease is clinically indistinguishable from idiopathic 
systemic sclerosis, genomic difference in both class II HLA and tumor necrosis 
factor (TNF) alleles suggest a difference in the mechanism of disease15.  Reports 
of the familial occurrence of systemic sclerosis are rare.  It is more common than 
would be expected by chance alone.  The concordance of SSc in identical twins is 
5 – 9 percent roughly 300 fold that of chance alone. 
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         A genetic contribution to disease is likely.  Studies of HLA phenotypes by 
serologic technique have suggested linkage of disease with HLA-A1, B8, DR3 
haplotype  or with DR3 DR5216,17. 
         Major histocompatibility complex analysis at the DNA level has revealed 
strong association with C4 AQO and DQ A2.  Furthermore, there are strong 
association of class II major histocompatibility complex alleles with serologically 
and clinically defined subjects of disease18. 
         First degree relatives of patients with SSc are mere likely to have serum 
antinuclear antibody19. 
ENVIRONMENTAL FACTORS 
         Environmental factors induce SSc-like diseases. Several reports describe 
chemical compounds within our environment and their ability to induce SSc-like 
diseases upon exposure (Table)20,21,22.  These substances can induce SSc-like 
diseases that can be distinguished from SSc by the following features: 
• Type of skin manifestation, in particular acrosclerosis, circumscribed and 
generalized morphea, fibrotic nodules, joint contractures. 
• Visceral involvement due to toxic damage of the liver, kidney, nervous 
system and muscles, angiosarcoma of the liver. 
• Laboratory findings of partial thrombocytopenia, and absence of 
autoantibodies. 
• Cessation or reversibility of the disease process after early discontinuation 
of the exposure. 
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Table : Environmental substances inducing scleroderma-like disease and       
their exposure 
 
 
Substances 
 
 
Exposure 
Chemical compounds 
Plastics (monomers) (vinyl chloride 
epoxy resins) 
Cleaners of vinyl chloride reactors  
Construction workers 
Solvents 
(Chlorinated)aliphatic and aromatic 
hydrocarbons 
 
Workers in dry cleaning chemical 
industry, pump attendants 
Pesticides Workers in agriculture, gardeners, 
chemical industry, patients 
(iatrogen, abuse) 
Drugs 
Bleomycin 
Pentazocine 
Ethoxisuximide 
Penicillamine 
 
 
Patients 
Other 
Paraffin (silicone*) 
Aniline contaminated rapeseed oil, 
salad oil (toxic oil syndrome),  
L-tryptophan 
 
Patients (breast augmentation*) 
 
 
Consumers 
Minerals 
 
Silica 
Miners, foundry workers/foremen, 
quarrymen, sandblaster, sandstone 
sculptors, glass grinders, cast 
polishers, dental mechanics 
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PATHOPHYSIOLOGY  
 
         Excessive collagen deposition causes skin and internal organ changes.  Many 
factors, including environmental factors can lead to immunologic system 
disturbances and vascular changes.  Endothelial alterations may lead to cascade of 
stimulatory changes that involve many cells, including fibroblasts, T lymhocytes, 
macrophages and mast cells.  In turn, the activated cells secrete a variety of 
substances, including cytokines and their soluble receptors and enzymes and their 
inhibitors.  These substances lead to changes in the extra cellular matrix 
compounds, including fibronectin; proteoglycans and collagen types I, III, V and 
VII.  Increased collagen deposition in tissues is a characteristic feature of SSc.  
Increased collagen production or disturbances in its degradation can cause 
excessive collagen deposition in tissues. 
         Fibrosis can be caused by profibrotic cytokines, including transforming 
growth factor-beta (TGF-beta), interleukin-4 (IL-4), platelet-derived growth factor 
(PDGF), and connective tissue growth factor.  The vasculopathy may be linked to 
TGF-beta and PDGF, while the diminution of lesional cutaneous blood vessels can 
be attributed to ant endothelial cell auto antibodies. The activation of the immune 
system is of paramount importance in the pathogenesis of SSc.  Antigen-activated 
Tcells, infiltrate early, infiltrate the skin and produce the profibrotic cytokine IL-4.   
B cells may contribute to fibrosis, as deficiency of CD 19 B-cell transduction 
molecule, results in decreased fibrosis in animal models. 
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         Different factors, including genetic, environment, vascular, 
autoimmunologic and microchimeric factors are involved in SSc pathogenesis.  
One theory states that antigens from the human leukocyte antigen (HLA) 
histocompatability complex, including HLA-B8, HLA-DR5, HLA-DR3, HLA-
DR52 and HLA-DQB2 are involved.  Some data suggest that apoptosis and the 
generation of free radicals may be involved in the pathogenesis of SSc. 
 
         In SSc, affected organs and systems include the skin, lungs, heart, digestive 
system, kidneys, muscles, joints and nervous system. 
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ALGORITHM FOR THE MULTIFACTORIAL PATHOGENIC 
MECHANISMS OF SYSTEMIC SCLEROSIS1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HOST 
Genetic subsceptibility 
Infection 
Environmental factors 
Microchimerism
VASCULAR 
Endothelial cell injury 
Vasoconstriction 
Vascular Occlusion 
Tissue hypoxia 
Fibroblast activation and Growth 
FIBROSIS
IMMUNE 
T cell activation 
Macrophage activation 
Auto antibodies 
Cytokines 
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CLINICAL FEATURES 
RAYNAUD’s PHENOMENON 1    
         Raynaud’s phenomenon, the initial symptom of SSc in the majority of 
patients, is a clinical expression of the abnormal regulation of blood flow resulting 
from vascular injury.  Injury to endothelial cells and basal lamina occurs early and 
is followed by proliferation of intima and smooth muscle cells with deposition of 
matrix and perivascular fibrosis leading to narrowing of the lumen and eventual 
obliteration of the vessel. 
         Raynaud’s phenomenon, which is defined as episodic vasoconstriction of 
small arteries and arterioles of fingers, toes, and some times tip of nose and 
earlobes.  Patients experience pallor and/or cyanosis following by rubor on 
rewarming.  Pollar and or cyanosis are usually associated with coldness and 
numbness of fingers and toes, and rubor with pain and tingling.  History of Digit 
pallor most reliable symptom for presence of Raynaud’s phenomen.             
         Raynaud’s phenomenon may precede skin changes by several months or 
even years in those patients who subsequently develop limited cutaneous form of 
SSc.  In diffuse cutaneous SSc skin changes are seen typically within a year of 
onset of Raynaud’s phenomenon.   
         After 2 or more years of Raynaud’s phenomenon, few patients who have this 
as their only symptom well subsequently develop SSc.   
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SKIN MANIFESTATIONS2 
         The skin disease of scleroderma follows a course characterized by three 
phases.  An inflammatory edematous phase, an endurative phase and an atrophic 
phase. 
         Three stages do not have distinct beginning and ending there is high degree 
of variability in the duration of inflammatory signs and in the severity and extent 
of the skin involvement. 
         In the Edematous phase, patient experiences puffiness, swelling and a sense 
of decreased flexibility of the skin especially in forearm, hands and degits as well 
as feet.  Fingers appear puffy with moon like fullness of finger tips and loss of 
digital creases, loss of finger pad and tapering of finger due to finger tip ischemia.  
This process may be last for months duration this time induration and skin 
thickening evident.  After inflammatory phase there is long course of progressive 
fibrosis of skin in diffuse cutaneous scleroderma and later atrophic phase sets in 
with loosening of skin. 
DIFFUSE CUTANEOUS SCLERODERMA 
         Characterized by tightening and thickening of skin that can involve 
extremities, chest, neck, face and abdomen.  Areas of mid back usually spared.  
Skin of the abdomen usually diffusely thickened.  Patients with diffuse skin 
disease a pulling, tight serration around upper chest and shoulder girdle a common 
complaint.  Anterior neck may develop horizontal fold of skin called the 
scleroderma ‘neck sign’.   
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         Pigmentary changes of the skin occur during the edematous and fibrotic 
stage but these changes vary in intensity and distribution.  Depigmentation occurs 
especially in scalp, eyebrows, upper back, chest, hand.  This vitiligo pattern gives 
the skin a ‘salt and pepper’ appearance because of perifollicular sparing of 
pigment loss. 
         Some patients develop diffuse tanning of skin.  Some have scattered patches 
of hyperpigmentation particularly over pressure points. 
         In the late stage of scleroderma, the skin becomes atrophic and thinned 
tethering secondary to fibrotic tissue binding to underlying structure. 
FACE2 
         Face becomes expressionless because of reduced capacity to smile or more 
eyelids or cheeks.  The opened mouth becomes circular with a remarkable 
reduction in maximum oral aperture (Microstomia).  Vertical lines or furrowing of 
the skin around the lips gives a pursed lip appearance.  The tight perioral skin 
sometimes makes the frontal teeth appear more prominent.  The nose becomes 
pinched and facial areas smooth so that face has a mouse like appearance 
(Mauskopf).   
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LIMITED CUATANEOUS SCLERODERMA 
         Skin thickening limited to sites distal to elbow and knee but also involving 
face and neck.  This subset frequently has features of the CREST =  
(C = Calcinosis; R = Raynaud’s phenomenon; E = Esophageal dysmotility:  
S = Sclerodactyly; T = Telangiectasia) 
LOCALIZED SCLERODERMA 
         Occurs most often in children and young women but can affect any age 
group. 
Two forms    1.  Morphea 
     2.  Linear scleroderma 
Morphea       -   Single or multiple plagues  of skin induration 
Linear scleroderma   -   Involves extremity or face. 
en coup de sabre: 
         Linear scleroderma of one side of forehead and scalp produces a 
disfiguration because it resembles a wound from a sword.  It may be associated 
with hemiatrophy of the same side of face. 
MUSCULOSKELTAL FEATURES 
         More than half the patients with SSc have arthralgia and arthritis.  A 
symmetric polyarthritis resembling rheumatoid arthritis may be seen.  Muscle 
weakness is usually present in patients with severe skin involvement most cases is 
due to disuse atrophy.  A few patients may develop myositis characterized by 
proximal muscle weakness and muscle enzyme elevation are identical to 
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polymyositis  (over lap syndrome).  In addition to terminal phalanges,  resorption 
of bone may invite rib clavicle and angle of mandible. 
GASTROINTESTINAL FEATURES   
         The Gastrointestinal involvement is more common in SSc.  Symptoms 
attributable to esophageal involvement are present in more than 50% of 
patients23,24.   
         Symptoms include Dysphagia, Regurgitation of gastric contents, epigastric 
burn.  Dysphagia particularly of solid foods may occur because of loss of 
esophageal motility due to neuromuscular dysfunction.  Manometry or 
cineradiography reveals decreased amplitude or disappearance of peristaltic waves 
in the lower two thirds of the esophagus. 
         Regurgitation and epigastric burn are due to reduced tone of the 
gastroesophageal sphincter and to dilatation of the distal esophagus.  Peptic 
esophagitis frequently occurs and may lead to strictures and narrowing of the 
lower esophagus.  Barrett’s metaplasia may develop, but transition to 
adenocarcinoma is uncommon25. Barium studies show dilatation, atony and 
delayed emptying.   
         Involvement of stomach present clinically as early satiety.  Vascular ectasia 
may develop in the stomach and intestine.  These dilated submucosal capillaries in 
the stomach appear an endoscopy as broad stripes – Watermelon stomach is a 
cause of bleed in SSc. 
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         Peristalitic abnormalities may delay gastric emptying and may affect motility 
of small and large intestines leading to pseudoobstruction and malabsorption due 
to bacterial overgrowth.  In addition diverticular ulceration, stenosis, chronic 
obstipation, mega colon and rectal prolapse have been described.  
         Liver is rarely involved primarily in SSc26. primary biliary cirrhosis can 
occur as an overlap syndrome. 
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PULMONARY INVOLVEMENT 
         Pulmonary involvement occurs in at least two thirds of SSc patients and now 
the leading cause of death in SSc. 
         The most common symptom is exertional dyspnea, after accompanied by a 
dry cough, non productive cough. 
         Physical findings include fine early inspiratory ‘Velero-like’ crackles at the 
lung base in case of interstitial lung disease. 
         The most sensitive method for detecting early lung disease in SSc is to 
perform pulmonary function testing. 
         Mild changes in function can be detected before any symptom develop.  The 
most common changes of pulmonary function testing are a reduced diffusion  
capacity (DLCO) or a reduction in lung volumes (forced vital capacity, FV) typical 
of a restrictive ventilatory defect with associated reduction in gas exchange.  Chest 
(X ray) film may show pattern of linear densities, mottling and honeycombing, 
involving most prominently to lower 2/3rds of lung. 
         Early interstitial pulmonary disease can be detected by high resolution 
computed tomography (HRCT) and Broncho Alveolar Large (BAL).  Active 
Inflamatory alveolitis gives a ground glan appearance of HRCT.  The recovery by 
Broncho Alveolar Large of increased number of cells mostly alveolar 
macrophages accompanied by neutrophils or esenophils is evidence of alveolitis.   
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         Individuals with limited systemic sclerosis may also develop interstitial lung 
disease but also have a risk for primary pulmonary hypertension, a complication 
most typical of longstanding disease. 
HEART 
         Cardiac involvement is often present, but rarely significant clinically.  Even 
dyspnea and retrosternal pain are attributed mainly to other organs such as lung or 
esophagus.  In addition, syncope and angina pectoris may be caused by either 
endothelial damage of small coronary arteries or myocardial fibrosis due to other 
basic diseases.  It is hard to prove the specificity of this involvement due to SSc 
itself.  The prevalence reported in the literature depends upon the diagnostic 
methods chosen.  Myocardial perfusion scintigraphy, ventriculography and 
echocardiography are the most sensitive techniques.  Clinically manifested forms 
have been described in 20-25 % with a 70% mortality after 5 years.  However, 
autopsy revealed  alterations such as myocardial fibrosis and pericardial effusion 
in 30-80% of patients27,28.  Myocardial fibrosis occurs as patchy or diffuse forms.  
Repeated episodes of ischemia and reperfusion lead to the destruction of the 
myocardium and replacement by connective tissue29.  In echo cardiographic 
studies of 80 SSc patients, hypokinetic alterations of the left ventricle were found.  
Echo cardiographic abnormalities such as conduction system disturbances (27%), 
signs of infarction (13.8%), and non specific ST and T wave changes (13.8%) 
were observed30.  
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KIDNEY 
         Affection of the kidney has the worst prognosis and highest mortality of all  
internal organs involved.  Clinically 10 - 40% are affected, but by autopsy, the 
figure is 80%33.  Patients with diffuse skin involvement carry a high risk of an 
acute renal crisis characterized by malignant arterial hypertension with headache, 
vision disturbances, cramps, left ventricular hypertrophy and retinopathy.  It 
generally manifests itself within the first 4 years.  However, the chronic form 
develops slowly over years and leads, in 50% of affects patients, to a moderate 
reduction of kidney function, often clinically in apparent.  Diagnostic criteria are 
proteinuria (< 1 g/24 h), azotemia (blood urea nitrogen (BUN) >25 mg/100 ml), 
arterial hypertension (> 140/90 mmHg) and reduction of the glomerular filtration 
rate.  Factors predictive to renal crisis are list in table34. 
Table   :   Factors predictive to renal crisis 
¾ Diffuse skin involvement 
¾ Rapid progression of skin thickening 
¾ Disease course < 4 years 
¾ Anti-RNA-polymerase III antibodies 
¾ Newly manifested anaemia 
¾ Newly manifested cardiac involvement 
¾        -   Pericardial effusion 
¾         -  Heart insufficieny 
¾ Preceded high-dose corticoid therapy 
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         The pathogenetic events are not completely understood.  The primary event 
seems to be the damage endothelial cells with thickening and proliferation of the 
intima with deposits of glycoproteins and mucopolysaccharides in the interlobular 
and small arcuade arteries.  These changes lead to narrowing or even obliteration 
of vessel lumina and ultimately to infarction of glomeruli and tubuli.  This is 
followed by platelet aggregation, adhesion and liberation growth factors.   
Sjögren Syndrome 
         Sjögren Syndrome is defined as an inflammatory disorder of salivary glands 
often characterized by circulating antibodies to Ro (SSA) and La (SSB) antigen.  
Depending on the diagnostic criteria used it occurs in 5 to 90% of SSc patients, in 
particular those with limited disease35,36. 
NERVES 
         Neurological manifestations include peripheral neuropathy with reduction in 
the conduction velocity and patients often show a prolonged response to local 
anaesthesia37.  Trigeminal neuralgia is found in about 4% of patients; carpal tunnel 
syndrome occurs in 3% of patients38,39. 
HEMATOLOGICAL ABNORMALITIES 
         Hematological abnormalities are mostly related to renal disease, 
microangiopathic hemolytic anaemia or from bleeding gastrointestinal 
teleangiectasias40. 
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PREGNANCY 
         Although pregnancies are less frequent in SSc, women can safely have 
healthy deliveries.  Steen has prospectively observed 91 pregnancies during a 10-
year period41.  No increase in the frequency of miscarriage was found except in 
those with long-standing diffuse scleroderma.  In 29% of pregnancies, preterm 
birth occurred and all but one of the infants survived.  While Raynaud’s 
phenomenon improved during pregnancy, esophageal reflux became worse.  After 
delivery some women with diffuse SSc had increased skin thickening.  In early 
diffuse SSc three patients suffered from renal crisis.  Therefore, patients with early 
diffuse SSc should wait until their disease stabilizes before becoming pregnant.  
High risk pregnancy management is required. 
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INVESTIGATIONS 
Lab findings (SSc) 
♣ Erythrocyte sedimentation Rate is increased 
♣ Hyper gammaglobulinaemia  
♣ Microangiopathic Haemolytic anemia 
♣ Increased creatine phosphokinase levels in patients with muscle 
involvement. 
♣ Increased urea and creatine levels in patients with kidney 
involvement 
♣ Proteinuria (more than 200 mg/24 hours) in renal involvement 
Immunological 
1. CRP  -  Increased 
2. Rheumatoid  factor – low titre – positive in 25% 
3. ANA  
4. Antipoisomerase antinuclear, anticentromere – Positive in limited 
cutaneous lesions. 
5. Anti Scl – 70 – positive 40% for diffuse cutaneous lesions. 
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SKIN BIOPSY 
         Epidermal skin appendages atrophy, and collagen fibres in the retricular 
dermis appear broad and hyalinized.  A loss of space between collagen bundles is 
noted. Mononuclear cells, mostly T cells form a variable perivascular infiltrate in 
the deep dermis and subcutis.  Later sclerotic changes predominate, the number of 
adnexal structures is reduced and loss of peri adnexal fat is noted. 
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MATERIALS AND METHODS 
 
         Patients who attended the Rheumatology  department from October 2005 to 
September 2006 were taken up for the study. 
         Systemic sclerosis was diagnosed in 25 patients as per the American College 
of Rheumatology (formerly American Rheumatism Association Scleroderma 
criteria cooperative study)42 criteria. 
 
Major Criteria 
 
         Sclerodermatous skin change in any location proximal to the 
Metacarpophalangeal joints 
 
Minor criteria  
 
♣ Sclerodactyly 
♣ Digital pitting scars of finger tips (or) 
♣ Loss of digital finger pad substance    and  
♣ Bibasillar pulmonary fibrosis 
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Diagnosis 
 
         One Major criteria (or) two or  three minor criteria 
         The sensitivity of these criteria was 97% and the specificity 98% by applying 
this American College of Rheumatology Criteria 
         The all 25 patients were analyzed from clinical, Biochemical, Immunological 
and radiological parameters.   
• Detailed clinical examination has done according to the proforma 
(attached).     
• Biochemical investigations done for all the patients (complete blood count, 
Renal Function Test, Liver Function Test).  
• Immunological investigations including: 
¾ Rheumatoid factor 
¾ Anti Nuclear Antibody 
¾ CRP (Creactic Protein)   all done. 
• Skin biopsy was done for 23 patients. 
• Radiological investigations consists of X ray chest and X ray hand. 
• Computed tomography chest was done for those who presented with 
Respiratory Symptoms. 
 
 
 29
 
 
• ECG (Electrocardiography) done for all patients. 
• Echocardiography was done who presented with cardiovascular symptoms. 
• Pulmonary Function Test was carried out for those who presented with 
Respiratory symptoms,  
• Ba Swallow, upper gastrointestinal endoscopy done for all the patients who 
attributed with symptoms of gastrointestinal tract. 
• Antitopoisomerase1 (anti Scl-70) not done because of lack of facility. 
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OBSERVATION AND INTERPRETATION  
AGE AND SEX PRESENTATION 
 
         Among 25 patients 2 were males and 23 were females (M : F ration 1 : 11.5). 
         The youngest was = 20 years 
         The oldest was      = 60 years 
Table 1     Analysis of Age and Sex presentation 
 
Age Male Female Total % 
20 – 30 0 4 4 16 
31 – 40 1 7 8 32 
41 – 50 1 8 9 36 
51 – 60 0 4 4 16 
 
         The mean age was   =  40 years 
         The highest incidence seen in  
         3rd decade    32%     and 
    4th decade    36% 
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SYMPTOM ANALYSIS 
 
         The initial presentation was skin symptoms in 13 patients (52%).  Arthralgia 
in 10 patients (40%) and Raynaud’s phenomenon in 2 patients (8%) and visceral 
symptoms (Dyspnoea on exertion) in one patient (4%). 
 
SYMPTOM ANALAYSIS – INITIAL PRESENTATION 
 
 
 
 
 
 
 
         Majority of patients had their symptoms between 30 – 50 years of age.   
 
 
 
 
 
Symptoms No.of 
patients 
% 
Skin 13 52% 
Arthralgia 10 40% 
Raynaud’s 
Phenomenon
2 8% 
Visceral 
symptoms 
1 4% 
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CUMULATIVE MANIFESTATIONS 
 
Symptom Analysis 
 
Symptoms No.of 
patients 
% South 
Indian 
Study43,44,45 
Skin 25/25 100% 98.9% 
Joint 20/25 80% 66.7% 
Raynaud’s 
phenomenon 
7/25 28% 28.2% 
Visceral 
manifestation
7/25 28%  
 
 
♦ 25 patients had skin changes (100%) 
♦ 20 patients had Arthralgia/Arthritis (80%) 
♦ 7 patients had Raynaud’s phenomenon (28%) 
♦ 7 patients had visceral symptoms (28%) 
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ANALYSIS OF CLINICAL MANIFESTATIONS 
SKIN INVOLVEMENT (CUTANEOUS) 
Clinical features No. of 
patients
% South 
Indian 
Study43,44,45 
North 
Indian 
Study12 
West 
Indian 
Study14 
Western 
Country46 
1.  Limited cutaneous 
 
a. Sclerodactyly 
 
b. Pigmentary changes 
(Hyper Pigmentation 
& Pepper salt 
pigmentation) 
 
10 
17 
 
40 
68 
 
33.3 
73.1 
 
10.3 
36.8 
 
14.2 
76.2 
 
0 
30.5 
2.  Calcinosis 0 0 1.1 2.3 41 8.9 
3.  Ulceration, Stellate scars 15 60 60 53 -- -- 
4.  Telangiectasia 0 0 1.1 2.3 41 8.9 
5.  Resorption Hand 1 4 13.2 NA NA NA 
6.  CREST 0 0 1.1 0 4 -- 
7.  Vasculopathy ulcer 1 4 4.1 -- 2 -- 
8.  Diffuse cutaneous 1 4 21.4 62.1 NA 5.4 
 
♦ Skin involvement was seen in all patients. 
♦ Pigmentary changes were more common (68%). 
♦ Sclerodactyly – next common manifestation (40%). 
 
 
 34
VASOSPASTIC CHANGES (Raynaud’s Phenomenon) 
 
 
Features No.of 
patients 
% South 
Indian 
Study43,44,45 
North 
Indian 
Study12 
West 
Indian 
Study14 
Western 
Country46 
Vasospastic 
changes 
7/25 28% 46.9 97.7 83.3 94.6 
Severity 
   Mild 
   Severe 
 
3/25 
4/25 
 
12 
16 
 
-- 
 
-- 
 
-- 
 
-- 
Involvement 
  Unilateral 
  Bilateral 
 
 
3/25 
4/25 
 
 
12 
16 
 
 
14 
23 
 
 
37.8 
62.2 
 
 
-- 
 
 
-- 
 
 
         Vasospastic changes were present in 7 patients.  This is comparatively less 
than other studies. 
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JOINT INVOLVEMENT 
 
 
Joint 
involvement 
Feataures 
No.of 
patients
% South 
Indian 
Study43,44,45 
North 
Indian 
Study12 
West 
Indian 
Study14 
Western 
Country46 
Minor 
Joints 
13/25 52 63.5 -- -- 
Major joints 7/25 28 36.5 -- -- 
 
41% 
Deformity 5/25 20 13.13 50 -- -- 
 
 
Joint manifestation were seen in 20 patients (80%). 
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Internal Organ Manifestations 
Gastro Intestinal Tract Manifestations 
 
         Out of 25 patients 18 patients presented with Dysphagia and Regurgitation.  
All the sympatomatic patients underwent Ba Swallow and upper gastro Intestinal 
Endoscopy. 
 
Symptoms No. of 
patients 
% Ba Swallow Upper gastro 
Intestinal 
Endoscopy 
Dysphagia 12/25 48% Dilated 
esophagus 
Normal 
Regurgitation 6/25 24% Normal Gastro 
esophageal 
Reflux 
disease 
 
         Patients presented with Dysphagia showed dilated esophagus in Barium 
Swallow studies (48%).   
Patients presented with Regurgitation showed gastro esophageal reflux 
disease on upper gastro intestinal endoscopy (24%). 
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RESPIRATORY SYSTEM 
 
         Out of 25 patients 4 had symptom of Respiratory system in the form of 
Exertional Dyspnea for which all patients were investigated with chest x ray, 
pulmonary function test and CT chest. 
 
Patient No. Symptom Chest X ray P.F.T. CT Chest 
Patient No.1 Exertional 
dyspnea 
B/L basal 
Haziness 
Mod to severe 
restrictive air 
way disease 
Interstitial 
lung disease 
Patient No.2 Exertional 
dyspnea 
B/L basal 
Haziness 
Mod to severe 
restrictive air 
way disease 
Interstitial 
lung disease 
Patient No.3 Exertional 
dyspnea 
Normal 
study 
Mild to moderate 
restrictive air 
way disease 
 
Normal study 
Patient No.4 Exertional 
dyspnea 
Normal 
study 
Mild to moderate 
restrictive air 
way disease 
 
Normal study 
 
   
Out of 4 patients who had symptoms of Exertional Dyspnea, X ray chest was 
normal for 2 patients. 
X ray chest :  showed basal (B/L) Haziness for another 2 patients. 
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PFT : showed mild to moderate Restriction air way disease for 2 patients who had 
X ray normal. 
PIT  : showed moderate to severe restriction airway disease for 2 patients who had 
x ray B/l basal Haziness. 
CT Chest : showed Interstitial lung disease for 2 patients who had X ray findings 
and PFT showed moderate to severe restriction air way disease.  Another 2 
patients CT normal study. 
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CARDIO VASACULAR MANIFESTATIONS 
 
         Out of 25 patients symptoms attribute to the Cardiovascular system were 
present in 4 patients (16%) for which they were evaluated for cardiac involvement. 
 
 
No.of patients 
 
 
Symptoms 
 
X Ray chest 
 
ECG 
 
Echo 
Patient No.1 Chest pain 
Dyspnea on 
exertion 
Enlarged 
cardiac 
silhovette 
sign 
Low voltage 
QRS complex 
and increase 
of T waves 
Moderate 
pericardial 
effusion 
Patient No.2 Chest pain 
and 
palpitation 
Normal Normal Mitral Valve 
prolapse 
disease  
Patient No.3 Chest pain 
Dyspnea on 
exertion  
Enlarged 
cardiac 
silhovette 
sign 
Increase of T 
waves 
Mild to 
moderate 
pericardial 
effusion 
Patient No.4 Dyspnea on 
exertion  
Basal 
Haziness 
 
Normal 
Pulmonary 
Hypertension 
secondary to 
ILD 
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RENAL SYSTEM 
         Out of 25 patients Renal involvement was absent in all patients.  Renal 
involvement was screened in the form of Proteinuria (more than 200 mg/24 hrs) 
and Hypertension and renal function tests. 
         Acute onset of malignant hypertension followed by rapidly progressive renal 
insufficiency is termed as Scleroderma renal crisis which is lkow in Indian 
patients47. 
Screeing for Renal Involvement 
 
No.of patients % Renal 
Function Test
24 Hours 
proteinuria 
B.P. 
25 0/25 Normal Normal Normal
 
INTERNAL ORGAN INVOLVEMENT 
 
 No.of 
patients
% South 
Indian 
Study43,44,45 
North 
Indian 
Study12 
West 
Indian 
Study14 
Western 
Country46 
Gastro 
Intestinal 
18/25 72 40.8 50.5 12 42 
Respiratory 4/25 16 19.4 57.4 12 70 
Cardio 
vascular 
4/25 16 9 11 3 20.2 
Renal 0/25 0 10 19.5 2 14.9 
 
 
 41
 
INVESTIGATIONS 
 
Sl. 
No. 
Investigations No.of 
patients 
% South 
Indian 
study 
North 
Indian 
Study 
Western 
study 
1. Hb < 10 gm% 4/25 16% 14.75 11.1 20.9 
2. ESR > 20 mm/hr 17/25 68% 70.5 75.3 70.0 
3. Proteinuria  
(> 200 mg/24 hrs) 
 
Rheumatoid Factor 
0/25 
 
 
4/25 
0% 
 
 
16%
10.2 
 
 
16.4 
 
 
 
12 
 
 
 
22 
4. ANA 9/25 56% 51.85 66.6 40.90 
5. CRP 8/25 40% 40.48 -- -- 
6. Skin Biopsy 23/25 92% 97.44% 80% -- 
 
1. Normocytic Normochromic anemia in 16% 43,44,45. 
2. ANA in low titre detected in 56%. 
3. Rheumatoid Factor was positive 16%. 
4. CRP was positive in 40%.  
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RESULTS 
♦ There were 2 males and 23 females giving a sex ratio of (1 : 11.5) 
♦ The age ranged from 20 – 60 years with a mean age of 40 years. 
♦ The highest incidence seen in 3rd decade (32%) 8 patients and 4th decade   
                (38%) 9 patients.           
♦ The initial presentation was skin manifestation (52%) Arthralgia (40%) 
Raynaud’s  (8%) Viseral symptom (4%). 
♦ Cumulative manifestations include skin (Cutaneous) 100%, Diffuse skin     
♦ Involvement seen in (4%), Arthralgia (80%).  
♦ No one  presented with fully developed CREST syndrome. 
♦ Calinosis    Nil 
♦ Reynaud’s    28% 
♦ Esophageal dysmotility   48% 
♦ Sclerodactyly   40%   
♦ Pigmentary lesions in the form of Hyperpigmentation and pepper salt  
♦ Pigmentation in (68%). 
♦ Joint involvement in the form of arthralgia was seen in 80%. 
♦ Gastro Intestinal system was involved in 72%. 
♦ Respiratory system was involved in 16%. 
♦ Cardiovascular system was involved in 16%. 
♦ Renal system was not involved even in one case. 
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Lab Results showed 
 
♦ Increased erythrocyte sedimentation rate in 68%43,44,45. 
♦ ANA in low titre detected in 56%43,44,45. 
♦ Rhematoid factor was postive in 16%. 
♦ CRP was positive in 40%. 
 
Out of 25 patients 
♦ Only one patient was having diffuse SSc. 
♦ Two patients were having undifferentiated SSc. (Having only Raynaud’s 
       Phenomenon  + skin changes + serology positive) 
♦ 22 patients were limited cutaneous SSc. 
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DISCUSSION 
 
         The various clinical features of systemic sclerosis of 25 patients have been 
analyzed in this study.  The results are compared with previous South Indian 
Study43,44,45, North Indian Study12, West Indian Study14 and Western country46 
study. 
         Out of 25 patients studied there were 2 males and 23 females with a sex ratio 
of 1 : 11.5 with female preponderance6,7.  Similar to universal picture the mean 
age of onset in this study was 40 years4,5,6,7 similar to other studies.  The peak age 
of onset occurred in 3rd and 4th decade in this study this is also comparable with 
other studies4,5,6,7.  It was very similar to other studies.   
         Raynaud’s phenomenon was the most common presenting symptom in North 
Indian12, West Indian13 and Western Country study46.  But in this study and South 
Indian study Raynaud’s phenomenon was low incidence43,44,45.  In this study 
Raynaud’s presentation was 28%.  The lower incidence of Raynaud’s in this study 
is probably due to hot climate prevailing in South India43,44,45. 
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         Vascular involvement in the form of vasculitic ulcers seen in 1 patient.  One 
patient had resorption of terminal phanges of fingers in radiograph of hands 
probably due to ischemia of the digits43,44,45. 
 
         In this study skin (cutaneous lesions) (100%) and arthralgia (80%) were the 
most common presenting manifestations which is similar to previous South Indian 
study and other studies43,44,45. 
         One of the patient in this study had diffuse skin involvement and internal 
organ involvement affecting lungs as Interstitial lung disease and pericardial 
effusion. 
         CREST syndrome was not noticed in any patient.  Similar to South Indian 
Study43,44,45. 
         Pigmentary changes were present in as high as 68% and this is comparable 
with West Indian study where the incidence of pigmentation was 76.2% and this 
may be because of Geographical location of these two zones which are closer to 
equator. 
         Sclerodactyly (40%) was seen to occur more commonly in our patients43,44,45. 
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         Skin Biopsy was done for 23 patients of them 21 (84%) had features of 
Scleroderma, Biopsy showed epidermal skin appendages atrophy and collagen 
fibres in the reticular dermis appear broad and hyalinized.  A loss of space 
between collagen bundles is noted.  Mononuclear cells, mostly T cells form a 
variable perivascular infiltrate in the deep dermis and subcutis. 
 
 
JOINT INVOLVEMENT 
 
         Joint manifestations were seen in 20 of the 25 patients.  Small joints 
involvement was seen more often (52%) similar to South Indian studies43,44,45.  
Major joint involvement is 36.5% .  Similar to South Indian study.  The incidence 
of joint involvement was more than Western studies 41%. 
         5 patients developed deformity with sclerodactyly is similar to South Indian 
study44,45,46. 
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GASTRO INTESTINAL TRACT 
         Gastro Intestinal involvement was present in 72%, compared to 40.8% South 
Indian, 50.5% in North Indian, 45% in Western Country studies. 
         Dysphagia was the commonest symptom, 12 of 25 patients presented with 
Dysphagia.  6 of 25 patients presented with Regurgitation. 
         Gastro Intestinal tract involvement was confirmed by Ba swallow and upper 
gastro dueodenal endoscopy. 
         Ba swallow showed Dilatation of esophagus in 12 cases who presented with 
Dysphagia. 
         Upper Gastro Intestinal endoscopy confirmed gastro esophageal reflux 
disease who presented with regurgitation. 
         This Gastro Intestinal involvement was similar to cohen et al and 
A.N.Malaviya’s study10. 
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RESPIRATORY SYSTEM INVOLVEMENT:  
 
         Exertional Dyspnea with bibasilar crepitations was present for four patients 
(16%).  Owens reported 70% incidence of lung involvement48.  For all 4 patients 
chest X ray was taken two of them had normal X ray chest.  Another two showed 
bilateral basal Haziness.  For all 4 patients pulmonary function test was done. 
         For those who showed normal X ray’s had mild to moderate restrictive air 
way disease. 
         For those who showed bilateral haziness had moderate to severe restrictive 
airway disease. 
         Computed tomography was done for all 4 patients.  CT chest was normal for 
whom X ray was normal. 
         CT showed interstitial lung disease for whom X ray showed bilateral 
haziness and pulmonary function test showed severe restrictive air way disease. 
 
 
 
 
 
 
 
 
 49
CARDIOVASCULAR MANIFESTATIONS 
 
         Symptoms attributable to cardiovascular system were present in 4 patients 
(16%).  Two of them had ECG changes of T wave abnormality. 
         Two of them ECG was normal.   
         Echocardiography showed moderate pericardial effusion for 2 patients and 
MVP Mitral Valve Prolapse in one patient.   
         The fourth patient developed moderate pulmonary hypertension secondary to 
Interstitial Lung Disease (ILD). 
         Cardiac involvement of 16% is similar to that of South Indian study43,44,45. 
         RENAL INVOLVEMENT in the form of significant Proteinuria and 
systemic hypertension was absent in all cases. 
         The incidence of renal crisis is found to be low in Indian Population47. 
 
 
 
 
 
 
 
 
 
 50
CONCLUSION 
 
           From this study of 25 patients of systemic sclerosis following 
conclusions were derived. 
1. Female preponderance (Female : Male 11.5 : 1) 
2. The highest incidence seen in 3rd and 4th decade. 
3. Limited cutaneous type was commoner than the diffuse SSc. 
4. Skin and joint manifestations were predominant 
5. Sclerodactyly and pigmentary changes are more common. 
6. Raynaud’s phenomenon is very much less probably due to climatic 
causes. 
7. Fully developed CREST was not present in this study. 
8. Resorptions of terminal phalanges were less common. 
9. Gastrointestinal involvement is more than other studies. 
10. Respiratory involvement was low compared to other studies. 
11. Cardiac involvement is less like other studies. 
12. Renal involvement is NIL in this study. 
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PROFORMA 
 
I.  PARTICULARS OF THE PATIENT 
 
Name      :    Age :   Sex : 
 
Hospital No.:    Occupation  : 
 
Address     : 
 
Chief Complaints: 
 
II.  HISTORY OF PROBLEMS:     Y/N 
 
HISTORY OF RAYNAUDS  PHENOMENON                                            
 
  1.  Digital blanching (Pallor)      Y/N  
     
              Cyanosis       (Blue)      Y/N 
              Rubor            (Red)      Y/N   
2. Involving one digit                                                                          Y/N                  
                                                                 
3. Involving several digits         Y/N                                           
 
4. Symptoms develops sensitivity to cold (Exposure)              Y/N  
   
5. Symptoms develops after a stressful condition                     Y/N 
 
6. Pitting scars in finger tips                                                     Y/N 
 
7. Swelling of fingers                                                                Y/N 
 
8. Stiffness of fingers              Y/N                                          
 
9. Sclerodactyly                                                                           Y/N                                  
 
10. Flexor contracture         Y/N  
 
11. Pulp Atrophy                                                                        Y/N                                           
 
12. Dry skin              Y/N                                           
13. Shiny skin                                                                                 Y/N 
14. Loss of hair         Y/N 
15. Nail fold Thrombi            Y/N                                 
16. Digital Infarct                     Y/N         
17. Digital Ulceration       Y/N   
18. Pseudo clubbing       Y/N 
19. Skin tightening        Y/N 
20. Skin Thickening       Y/N 
21. Shiny appearance        Y/N  
22. Darkening of skin       Y/N 
23. Absence of skin wrinkling      Y/N  
24. Mask like facies        Y/N 
25. Pinched up nose        Y/N 
26. Microstomia        Y/N 
27. Pigmented skin        Y/N 
28. Depigmented skin (Salt : Pepper apperance)     Y/N                                  
29. Telangiectasia          Y/N                                           
30. Early Morning stiffness      Y/N                             
31. Fatigue           Y/N                                           
32. Musculo articular pain       Y/N 
33. Arthritis         Y/N 
34. Arthralgia        Y/N 
35. Primal muscle weakness      Y/N 
36. Dry mouth        Y/N 
37. Hypothermia         Y/N 
38. Trigeminal neuralgia       Y/N 
39.  Heart burn        Y/N 
40. Dysphagia        Y/N 
41. Cough         Y/N 
42. Dyspnoea        Y/N 
43. Palpitation        Y/N  
44. Abd pain         Y/N 
45. Constipation        Y/N 
46. Distention        Y/N 
47. Obstruction        Y/N 
PAST HISTORY        
Hypertension         Y/N 
Diabetes Mellitus        Y/N 
Tuberculosis         Y/N 
Bronchial Asthma        Y/N 
Chronic Obstructive Pulmonary Diseases     Y/N 
Heart disease         Y/N 
Kidney Disease        Y/N 
 
Malignancy         Y/N 
Connective Tissue Disease       Y/N 
PERSONAL HISTORY       
 
Smoking         Y/N   
Alcohol         Y/N 
Tobacco chewing        Y/N 
Premarital contact        Y/N 
Extra marital contact       Y/N 
FAMILY HISTORY 
 
History of similar illness in family                          Y/N                   
 
CLINICAL EXAMINATION 
 
♦ Conscious 
♦ Oriented 
♦ Temperature 
♦ Anemia 
♦ Clubbing 
♦ Icterus 
Lymphadenopathy 
 
♦ Pulse : 
 
♦ B.P. : 
 
♦ R.R. : 
 
 
FACE 
 
♦ Mask like facies 
♦ Absence of normal skin wrinkling 
♦ Pinched up nose or beaking of the nose 
♦ Hide bound, Tight skin of face 
♦ Puckered mouth 
♦ Shiny skin 
♦ Pigmented/Depigmented skin 
♦ Telangiectasia 
 
C.V.S. 
 
♦ S1 
♦ S2 
♦ S3 
♦ Murmur 
♦ Pericardial Rub 
R.S. 
♦ N.V.B.S. 
♦ Added sounds 
♦ Crackles 
♦ Rhonchi 
♦ Pleural rub 
♦ Tubular 
♦ Cavernous 
P/4 
♦ Soft 
♦ Tenderness 
♦ Hepatomegaly 
♦ Splenomegaly 
C.N.S. 
              FND 
 
URINE ROUTINE EXAMINATION 
♦ Albumin 
♦ Sugar 
♦ Deposits 
24 hours urine protein  
 
 
 
 
 
INVESTIGATIONS 
1. TC: 
2. DC: P_____________ L ______________ E _________________ 
3. ESR : 
4. Hb: 
5. Peripheral Blood smear study: 
6. Blood sugar 
7. Blood urea 
8. Serum Creatinine 
9. LFT 
10. RA Factor 
11. ANA : 
12. Pulmonary Function Test: 
13. X ray chest PA 
14. CT Chest 
15. ECG 
16. Echo 
17. Ba Swallow 
18. Skin Biopsy 
 
 
 
 
 
 
 
 
 
SCLERODERMA FACIES 
 
 
 
 
BARIUM SWALLOW SHOWS DILATED ESOPHAGUS 
 
 
 
 
 
PITTED SCARS ON FINGER TIPS 
 
 
 
 
 
 
VASCULITIS ULCER 
 
 
 
 
 
X-RAY CHEST PA VIEW SHOWS  
BILATERAL BASAL HAZINESS 
 
 
 
 
FRONTAL TEETH APPEAR MORE PROMINENT BECAUSE OF TIGHT 
PERIORAL SKIN 
 
 
 
 
 
COMPUTED TOMOGRAPHY – CHEST SHOWS  
INTERSTITIAL LUNG DISEASE (I.L.D) 
 
 
 
 
 
COMPUTED TOMOGRAPHY – CHEST SHOWS  
INTERSTITIAL LUNG DISEASE (I.L.D) 
 
 
 
 
 
X-RAY HAND RESORPTION 
 
 
 
 
 
 
SCLERODACTYLY WITH DEFORMITY 
 
 
 
 
 
BARIUM SWALLOW SHOWS DILATED ESOPHAGUS 
